In patients in the advanced stages of lung cancer, finding target molecules, such as EGFR, ALK, and ROS1, is significant for making treatment decisions; as such, it is necessary to perform molecular testing at the time of initial diagnosis [14]. This evidence concerns the gene EGFR and lung carcinoma.